Glycosylation is the most abundant and complex posttranslational modification to be considered for recombinant production of therapeutic proteins. Mucin-type (GalNAc- 
Introduction
Posttranslational modifications (PTMs) of recombinant protein therapeutics are important with glycosylation being by far the most important PTM to address. Nand O-linked glycosylation are often essential for biological activity and pharmacokinetic properties (Li and d'Anjou, 2009) . Recombinant production of glycoprotein therapeutics has so far generally aimed to mimic the glycosylation found on naturally produced human glycoproteins primarily to avoid adverse immunological reactivity and improve circulatory half-life. Considerable efforts have thus been devoted to design and optimization of host cells aimed for recombinant expression of biologics. Significant success has been achieved with designed N-glycosylation in both higher eukaryotes such as plants (Strasser et al., 2008; Gomord et al., 2010) , lower eukaryotes such as yeast (Gerngross, 2004) , and even extended to some prokaryotes (Hug et al., 2011) . In contrast, limited progress has been made with respect to O-glycosylation. O-glycosylation is one of the most complex regulated PTMs of proteins and also one of the least understood (Bennett et al., 2011) . Oglycosylation is initiated by a family of up to 20 UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts), which allows for huge variability of Oglycan attachments to proteins in different cells, a feature not found for most other types of protein glycosylation. Engineering glycosylation in host cells may also aim to produce aberrant truncated glycoforms that mimic those found in disease with intend to e.g. target proteins to antigen presenting cells and augment immunity in vaccine strategies. It may therefore be desirable to build glycosylation capacity in host cells de novo in order to attain complete design freedom without extensive requirement for gene elimination. This is particularly desirable for mammalian O-glycosylation where cell-specific repertoires of the many GalNAc-Ts direct the glycosylation capacity.
Most glycoprotein therapeutics are produced in Chinese hamster ovary cells (CHO) (Durocher and Butler, 2009) . CHO cells produce mono-and disialylated core 1 (Galβ1-3GalNAcα1-O-Ser/Thr) O-glycan structures (Sasaki et al., 1987) . Recently glycosylation in higher eukaryotes. The yeast Pichia pastoris was previously used as a model system to engineer the first step of human O-glycosylation from scratch (Amano et al., 2008) . However, since ER localized O-mannosylation precedes GalNAc O-glycosylation in the Golgi apparatus, considerable O-mannosylation was found on glycoproteins expressed in the engineered cells. This competing Omannosylation was partly blocked by co-culturing in rhodanine-3-acetic acid, but complete elimination of O-mannosylation is presumably not possible, as knock-out of three or more of the seven O-mannosyltransferases is lethal (Strahl-Bolsinger et al., 1999 ).
Plants are emerging as an attractive alternative platform for expression of glycoproteins (Cox et al., 2006; Sainsbury and Lomonossoff, 2008; Pogue et al., 2010) . Several studies have demonstrated that plants can efficiently produce complex mammalian proteins, such as monoclonal antibodies with humanized N-glycan structure (Cox et al., 2006; Strasser et al., 2008; Castilho et al., 2010; Pogue et al., 2010) . Whereas plants and mammalian cells have identical core N-linked glycosylation, plants do not perform GalNAc O-glycosylation (Gomord and Faye, 2004; Saint-Jore-Dupas et al., 2007; Bennett et al., 2011) . Plants, however, produce another type of O-glycosylation, which is primarily found in the hydroxylproline (Hyp) rich glycoprotein (HRGP) superfamily, where e.g. arabinogalactan (AG) and arabinosides are attached to hydroxyprolines (Hyp's) of arabinogalactan proteins (AGPs) and extensins, respectively. This type of O-glycosylation requires the initial action of prolyl 4-hydroxylases (P4Hs), and although a consensus motif for this type of modification has not been defined, it appears to occur mainly in regions with high density of Pro residues (Shimizu et al., 2005; Estevez et al., 2006; Jamet et al., 2008; Lamport et al., 2011) . The Hyp contiguity hypothesis predicts arabinosylation of contiguous Hyps (≥2) with extensin type β -linked arabinofuranosides (β-Arafs) of up to four residues in length and galactoarabinosylation of clustered noncontiguous Hyp residues in AGPs (Shpak et al., 1999; Zhao et al., 2002; Tan et al., 2010) . Several small peptide hormones and plasma membrane kinases involved in cell wall sensing have also been shown to be arabinosylated (for recent reviews see (Ringli, 2010; Matsubayashi, 2011) ). While small peptide hormones and plasma membrane kinases invariably carry the Hyp-(β-Araf) 3 side-chain, extensin β -Araf side-chains may be shorter or additionally capped with a α -linked Araf. The amino acid sequence 'SerProProPro(Pro)' directs arabinosylation in extensins (Kieliszewski et al. 2011 ), 1 0
MUC1 of MUC1-YFP is degraded in BY-2 cell medium
Repeated failed attempts to detect MUC1 expressed alone or in fusion with the carrier YFP protein in the BY-2 media fractions prompted us to look further into the fate of in particular MUC1-YFP. A BY-2 transgenic cell line stably expressing MUC1-YFP and the O-glycosylation machinery T2-2A-CytoEpi failed to produce detectable levels of the MUC1-YFP protein (37 kDa) in BY-2 medium as evidenced by MUC1 specific Western blot analysis (data not shown). His-tag affinity purification of MUC1-YFP from spent medium of the BY-2 cell line was also not possible (data not shown). Concentration by hydrophobic interaction chromatography (HIC), however, revealed the presence of substantial amounts of fluorescent protein ( Fig. 3A) , which migrated as a 25 kDa protein on SDS-PAGE gels and reacted with a GFP polyclonal Ab (Fig. 3B+C ), but not with a MUC1 specific MAb (Fig. 3D ). The yield was estimated to be approximately 25 mg/L as judged from Coomassie stained SDS-PAGE (Fig. 3B) . Based on this, we concluded that MUC1-YFP was partially degraded in the BY-2 medium resulting in release of the C-terminal His-tag and the N-terminal MUC1 sequence. A construct expressing a fusion of an AGP type (SP) 10 glyco-module (Xu et al., 2010) to the C-terminal of MUC1 also failed to confer accumulation of MUC1 in the BY-2 medium (data not shown).
Embedding and glycosylation stabilize secreted MUC1 in BY-2 medium
Previous studies have shown that embedding of small otherwise labile proteins in GFP may confer increased stabilization (Kobayashi et al., 2008) . Accordingly, we prepared an embedded MUC1 construct, designated GF(MUC1)P, where a MUC1-2.5TR sequence flanked C-terminally with a (His) 8 -and N-terminally with a Myc tag, was embedded in the loop between Asp196 and Gly197 of GFP ( spectrometry (MALDI-TOF-MS) confirmed a uniform incorporation of 3 GalNAc residues (Fig. 5A ). However, evidence was also found for modification of Pro to Hyp, and of Hyp with 3 (~45%) and less frequently 6 (~5%) arabinose residues attached (Fig. 5A ). The MUC1 repeat contains 5 proline residues of which up to 4 were hydroxylated.
O-glycosylation further stabilizes MUC1
An in vitro degradation model was used to evaluate the effect of Oglycosylation on MUC1 stability in BY-2 medium. Purified GF(MUC1)P of BY-2 cell lysates, purified glycosylated Tn-GF(MUC1)P of BY-2 medium, and purified MUC1-YFP and Tn-MUC1-YFP, transiently produced in N. benthamiana plants,
were added to 7 day-old BY-2 wt medium with and without prior boiling (Fig. 4) .
While all MUC1 substrates were stable in boiled medium ( Fig. 4C ), only the Tn-GF(MUC1)P was stable in non-boiled medium after 24 h incubation ( 
2,2-Dipyridyl inhibits Pro Hydroxylation and Arabinosylation in BY-2 cells
In order to block or reduce formation of the observed endogenous PTMs on the GF(MUC1)P reporter substrate, three inhibitors of proline hydroxylase activity were selected (ethyl-3,4-dihydroxybenzoate (EDHB), 3,4-dehydroproline (DHP) and 2,2-dipyridyl (2,2 DP)) (Schmidt et al., 1991; Velasquez et al., 2011) and added to the BY-2 medium at various concentrations. Addition of all three inhibitors reduced the accumulated level of GF(MUC1)P in the medium as well as cell growth rates (Supplemental Fig. S5 ). Only 2,2 DP was able to efficiently suppress proline hydroxylation of MUC1 tandem repeats and the accompanying attachment of pentose sugars ( Fig. 5B and Supplemental Fig. S6 ). The larger arabinogalactans and the short arabinofuranosides are the only known Hyp-linked glycans in plants (Lamport et al. 2011 ). In the transient expression system, addition of the proline hydroxylase inhibitors conferred a minor reduction on the proline hydroxylation level from ~20%
to ~10% without an accompanying reduced level of expressed MUC1-YFP (Supplemental Fig. S7 ). Fig. S2A) . Surprisingly, removal of the Nterminal Hemagglutinin (HA) tag in HA-T2-2A-CytoEpi markedly improved production of the two functional enzymes in stable implementations (Fig. 2B ).
Degradation of all 2A-derived polyproteins was observed as evidenced by Western blot analysis (Supplemental Fig. S2B ). Also, the one-gene-one-promoter O- We previously observed that the MUC1 reporter substrate was somewhat instable when expressed transiently in plants (Yang et al., 2012) . Here, we observed even more severe problems with stability of the small MUC1 reporter substrate whether expressed alone (MUC1) or in fusion with the carrier YFP (MUC1-YFP) ( Fig. 1 and 3 ). We also showed that incubation of non-glycosylated and glycosylated MUC1-YFP in BY-2 medium conferred a complete protease mediated breakdown of 1 4
MUC1, resulting in the trimmed resistant stable barrel YFP structure. We therefore tested an alternative strategy where we embedded 2.5 tandem repeats of MUC1 with tags into GFP (Fig. 4A) as previously proposed by Kobayashi and co-workers (Kobayashi et al., 2008) . These authors demonstrated that 67 amino acid residues could be inserted into a loop between the β -strands located on the opposite side of the N-and C-termini of the GFP protein without substantial loss of fluorescence capacity.
Co-expression of the embedded construct GF(MUC1)P with the O-glycosylation machinery CytoEpi-T2 resulted in secretion of GalNAc-glycosylated GF(MUC1)P in the BY-2 medium (Fig. 5A ). MALDI-TOF-MS analysis revealed that GF(MUC1)P was uniformly glycosylated with 3 GalNAc residues, which corresponds to the substrate specificity of GalNAc-T2 (Bennett et al., 1998) . Approx. 50% of the GF(MUC1)P in the BY-2 medium further contained up to 4 Hyps as well as 3 and 6
arabinose residues (Fig. 5A ). Introduction of a single construct for expression of GF(MUC1)P and the O-glycosylation machinery CytoEpi-2A-T2, resulted in moderate accumulation of GF(MUC1)P (~5 ug/g fresh weight) in Arabidopsis ( Fig.   6B ), which was modified with 0-3 GalNAc residues, 0-4 proline hydroxylations and minor arabinosides (Fig. 6D ).
In agreement with our previous transient implementation (Yang et al., 2012) , introduction of the mature secreted form of the cytokine IFNα2B in Arabidopsis resulted in expression of the intact product, which was glycosylated when coexpressed with the O-glycosylation machinery CytoEpi-T2 (Fig. 2C ). Likewise, a 1.2 TR of MUC16, which also realizes a full structural unit with 3 potential Nglycosylation and up to 30 O-glycosylation sites, was expressed and shown to be Nglycosylated by the endogenous N-glycosylation machinery in BY-2 cells (Supplemental Fig. S1 ). Explanations for the apparent instability of the small MUC1- (Schaller, 2004; Smalle and Vierstra, 2004; Benchabane et al., 2008) . The high protease activity in the BY-2 medium (Robertson et al., 1997; Okushima et al., 2000) may for production of some pharmaceutical proteins require tailored knock-out 
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). We demonstrated that substantial reduction in Hyp modifications could be achieved by addition of the 2,2 DP inhibitor but, clearly, targeted knock-out of one of more P4Hs acting on the expressed proteins of interest would be more efficient.
Several reports suggest involvement of the three P4Hs, AtP4H2, AtP4H5, and AtP4H13, in hydroxylation of contiguous Pro motifs in particular (Hieta and Myllyharju, 2002; Tiainen et al., 2005; Keskiaho et al., 2007; Velasquez et al., 2011) , perhaps pointing to these enzymes as first targets for engineering plants with knock-
out of plant-specific proline hydroxylation and Hyp-linked arabinosylation. The clinical significance of proline hydroxylations and Hyp-linked arabinosylations is unknown or at best speculative (Petersen et al., 1998; Leonard et al., 2005; Altmann, 2007; Manduzio et al., 2012 , Pinkhasov et al. 2011 (Strasser et al., 2008; Kaulfurst-Soboll et al., 2011; Nagels et al., 2011; Schoberer and Strasser, 2011) , to generate more general platforms for expression of glycoprotein pharmaceuticals in plants.
MATERIALS AND METHODS

Transformation and Plant Growth Condition
Bright Yellow 2 (BY-2) suspension cells were cultivated by shaking (25°C, 130 rpm) in the dark. Transformation and fermentation of BY-2 cell are described in (Mayo et al., 2006) . Agrobacterium tumefacience strain C58C1 pGV3850 was used for both stable transformation and transient agrobacterium mediated expression.
Transformation of Arabidopsis thaliana was performed as described (Horsch et al., 1986) . Growth conditions and transformation of transgenic Arabidopsis thaliana plants were performed as described (Egelund et al., 2007) . Transformation and maintenance of Lemna minor were done as described (Rival et al., 2008) .
Agrobacterium mediated expression was done essentially as described in our previous study (Yang et al., 2012) .
DNA Constructs for Plant Transformation
Open source vectors used for Agrobacterium mediated expression and or ii) PpSP derived from Physcomitrella patens aspartic protease (EMBL accession number AJ586914: Sequence: MGASRSVRLAFFLVVLVVLAALAEA), and these were generated as described previously (Yang et al., 2012) . A novel construct with 2.5 tandem repeat (TR) sequence of MUC1 embedded in GFP (GF(MUC1)P) was prepared as follows ( Fig. 1 ). The MUC1-2.5TR sequence was inserted into GFP 1 8
protein after Asp196 into the NcoI site of modified GFP (MfGFP) (Kobayashi et al., 2008) , followed by PCR mediated insertion of the signal peptide for secretion. The primer sets were SSGFPfor (5'-gagctccatgggtaagactaatctttttctctttctcatcttttca cttctcctatcattatcctcggccgagcaagtgagcaagggcgaggagct-3') and GFPrev (5'-catatgcttgtacagctcgtccatg-3') and the resulting PCR fragment were cloned into SacI site of pPS48 under control of the Ubi promoter and the Ubi terminator. Finally the whole expression cassette was inserted into HindIII site of pCAMBIA2300, yielding
Design of the O-glycosylation machinery was essentially as described 
PpSP-MUC1-3.5TR-YFP(His
) 6 -35STerm;35SPro-T2-2A-CytoEpi-35STerm (MUC1- YFP-T2-2A-CytoEpi) (Fig. 1C).
Preparation of Total Protein Extracts
Approximately one gram of freshly harvested leaves or roots were frozen in liquid N 2 and comminuted using a pestle and mortar with 2 ml extraction buffer A (50 mM NaPO 4 , 250 mM NaCl, 5 mM Imidazol, pH 8.0) containing Complete Proteinase
Inhibitor (Roche) and 1 mM phenylmethanesulfonylfluoride. The sample was incubated for 10 min on ice and insoluble material was pelleted by centrifugation (20,000 x g) for 10 min, the supernatant was recovered and stored at -20°C.
SDS-PAGE Western Blotting
SDS-PAGE Western blot analysis was performed as previously described (Petersen et al., 2009). Monoclonal antibodies (MAbs) to T7-tag and MUC16 (M11)
were obtained from Invitrogen and Dako, respectively. MAbs to MUC1 and GalNAc-MUC1 (Tn-MUC1), 5E10 and 5E5, respectively, were described previously (Tarp et al., 2007) . HRP-conjugated Vicia villosa lectin (VVA; EY Laboratories) was also used for detection of Tn glycoforms.
Hydrophobic Interaction Chromatography
MUC1-YFP was purified by hydrophobic interaction chromatography (HIC)
using ÄKTA FPLC System with a HiTrap HIC column (5 ml, GE), pre-packed with Phenyl Sepharose 6 Fast Flow. BY-2 cell medium fraction (100 ml), additionally adjusted to include 3 M NaCl and 20 mM Tris-buffer (pH 8.0), was centrifuged 25,000 x g for 20 min. The supernatant was loaded (2ml/min) to the pre-equilibrated HIC column and then washed with 20 ml wash buffer, i.e. 2 M NaCl in 20 mM Trisbuffer (pH 8.0). MUC1-YFP was eluted by water in 10 fractions of 2 ml.
Ni-Chromatography
Cleared supernatants (50 ml, 20,000 x g for 30 min) were incubated with 0.5 ml of Ni-NTA agarose beads (Qiagen) for 2 h (4°C) under gentle rolling. Beads were washed for 10 min with 20 ml of wash-buffer (50 mM NaPO 4 , 250 mM NaCl, 20 mM Imidazole, pH 8.0), and eluted with 5 x 1 ml of elution-buffer (50 mM NaPO 4 , 250 2 0 mM NaCl, 250 mM Imidazole, pH 8.0).
Degradation Study of MUC1-YFP and embedded GF(MUC1)P in BY-2 medium
Culture medium (50 ml) of wild type BY-2 cells grown for 7 days was collected by centrifugation 10,000 g for 5 min (wt BY-2 medium fraction). Ca. 5 μ g purified MUC1-YFP (transiently produced in leaves of N. benthamiana plants with/without O-glycosylation machinery) and embedded GF(MUC1)P (purified from intracellular or extracellular of BY-2 cells with/without O-glycosylation machinery), was added to 7 day old 1 ml of un-boiled or boiled (for 15 min) wt BY-2 medium fractions, which was further incubated at 25°C under shaking (130 rpm) for an additional 24 h or 48h under the same conditions and ultimately subjected to MUC1
and Tn-MUC1 specific (MAb 5E10 and 5E5, respectively) Western blot analysis.
Endo-Asp Digestion of MUC1-TR and Sample Purification
Purified MUC1-YFP (~25 µg) was incubated with 1 µg endoproteinase Asp-N from Pseudomonas fragi (Roche) in 300 µL 100 mM Tris-HCl (pH 8.0) for 16 hours at 37°C under shaking (600 rpm). In the case of embedded GF(MUC1)P, in-gel digestion (Shevchenko et al., 2006 ) was used to release MUC1 tandem repeats from the GFP protein, as in-gel protein digestion of embedded GF(MUC1)P was found to
give a better recovery compared to the 'in-solution' method. Both Asp-N (10 ng/μl) and trypsin (10 ng/μl) were added into the digestion buffer (25 mM NH 4 HCO 3 , 10% acetonitrile (ACN)). The digest was cleaned on a C18 Zip-Tip (Millipore). Briefly, the digestion mixture was dissolved in 20 μL 0.1% trifluoracetic acid (TFA) and drawn through the column, desalted with 0.5% formic acid, and eluted with 100% ACN.
Matrix-Assisted Laser-Desorption Time of Flight Mass Spectrometry (MALDI-TOF-MS)
Lyophilized peptides were dissolved in 20 μl water. The MALDI matrix 2,5-dihydroxybenzoic acid (Sigma-Aldrich) was dissolved (25 g/L) in a 1:1 mixture of water and methanol. Samples were prepared for analysis by placing 0.5 μ l of sample solution on a MALDI target, followed by 0.5 μ l of matrix solution which was then air dried. All mass spectra were acquired in the linear mode on a Voyager-Elite MALDI C r e u z e n e t C , B e l a n g e r M , P l a n t J 4 1 : CytoEpi-T2. The isolated proteins were added to 7 day-old un-boiled (-) or boiled (+)
wt BY-2 medium fractions, which were further incubated for up to 24 h under the same conditions. Approximately 5 μ g purified proteins were added to 1 ml BY-2 medium fractions, respectively, of which ca. 15 μ l were loaded and blots probed with anti-MUC1 MAb 5E10. The corresponding Tn-MUC1 specific Western blot using MAb 5E5 is presented in Supplemental Fig. S3 . inhibitor. Growth medium was exchanged at day 7 with fresh medium including 200 µM of 2,2-Dipyridyl (2,2 DP) followed by incubation at similar growth conditions. The analysis revealed the pressence of 3 moles of attached GalNAc, i.e. complete GalNAc-T2 mediated GalNAc occupancy of sites, with varying proline hydroxylations of up to 4 moles per tandem repeat. Hydroxylated MUC1 peptides were further modified by attachment of mainly by 3-, and less frequently by 6 arabinose residues. (B) MALDI-TOF-MS analysis of GF(MUC1)P co-expressed with CytoEpi-T2 in BY-2 cells grown in the pressence of prolyl 4-hydroxylase (P4H) inhibitor. Growth medium was exchanged at day 7 with fresh medium including 200 µM of 2,2-Dipyridyl (2,2 DP) followed by incubation at similar growth conditions.
